Alamar Biosciences has launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, a workflow that enables researchers to run NULISA panels on microsamples collected at home. The kit supports dried blood spot and dried plasma spot samples collected on leading third-party remote sampling devices.
The workflow extends NULISA into longitudinal, decentralized, and population-scale research in neurology, inflammation, and population health. These study designs can face limits when they depend on venous blood draws alone.
“This launch reflects our commitment to making proteomics more accessible for population-based screening programs,” advises Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “By combining the NULISA platform’s attomolar sensitivity with a standardized extraction workflow for microsamples, we are empowering researchers to unlock high-quality multiplexed proteomic data from remotely collected samples that were previously out of reach.”
Dried blood spot sampling converts a few drops of blood into a dried specimen that can ship at ambient temperature. This model can reach participants outside major research centers, reduce dependence on scheduled phlebotomy, and support repeat sampling in studies that follow people over time.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
For proteomics, researchers still need to recover protein signals from small sample volumes across different collection devices while preserving low-abundance biology. Alamar designed the NULISA DBS Extraction Kit to address these challenges through a standardized workflow for multiplex protein measurement from remotely collected samples.
The workflow connects remote sample collection to Alamar’s NULISA technology. The platform detects low-abundance protein biomarkers in non-invasive biofluids with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and automated workflows.
“The ability to generate high-quality proteomic data from a fingerstick blood sample is a transformative capability for population studies and longitudinal research,” remarks Amanda Heslegrave, UCL UKDRI, Co-lead Biomarker Factory. “A standardized extraction workflow like the NULISA DBS Extraction Kit makes it practical to integrate micro-sampling into remote collection protocols without sacrificing sensitivity or reproducibility.”
The kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party micro-sampling devices, including Capitainer, Telimmune, Mitra, and Tasso. In validation work, Alamar showed 85–95 percent target detectability across its NULISA CNS and Inflammation panels on most supported micro-sampling platforms.
This article is based on a press release issued by Alamar Biosciences.
